Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Jan
10
2024
EU Corporate Sustainability Due Diligence Directive Nearly Final Hunton Andrews Kurth
Jan
10
2024
California Court Applies Proposition 65 Safe Harbor in Dismissal Keller and Heckman LLP
Jan
9
2024
MoCRA Update for Starting the Year Off Right Beveridge & Diamond PC
Jan
9
2024
FDA’s Marketing Denial Order Issued to Bidi Vapor’s Non-Tobacco Flavored ENDS Products are Set Aside and Remanded by the 11th Circuit Court of Appeals for being Arbitrary and Capricious Keller and Heckman LLP
Jan
9
2024
5th Circuit Issues Blistering Critique of FDA’s Handling of PMTAs for E-Cigarettes Keller and Heckman LLP
Jan
9
2024
CORE Releases 2022 Annual Outbreak Report Keller and Heckman LLP
Jan
9
2024
Malta Initiative Survey on OECD Test Guidelines and Guidance Documents Will Close January 12 Bergeson & Campbell, P.C.
Jan
9
2024
Blazing Trails: Exploring ESOPs in the Cannabis Industry Bradley Arant Boult Cummings LLP
Jan
8
2024
Gold Dome Report – Legislative Day 1 (2024) Nelson Mullins
Jan
8
2024
HHS, ONC HTI-1 Final Rule Introduces New Transparency Requirements for Artificial Intelligence in Certified Health IT Mintz
Jan
8
2024
Extended Producer Responsibility for Packaging: What’s Ahead in 2024 Hunton Andrews Kurth
Jan
5
2024
Trending in Telehealth: December 21, 2023 – January 3, 2024 McDermott Will & Emery
Jan
5
2024
Texas Urges Federal Court to Toss Tofurky Challenge of Labeling Law Keller and Heckman LLP
Jan
5
2024
McDermottPlus Check-Up: January 5, 2024 McDermott Will & Emery
Jan
5
2024
Hospital and MA Plan Considerations for CMS Final Rule to Remedy 340B Drug Payment Policy Epstein Becker & Green, P.C.
Jan
4
2024
With Increased New York Minimum Wage Come Modified Obligations Under State Wage Orders Jackson Lewis P.C.
Jan
4
2024
2023: A Good Trip Around the Sun for Psychedelics Bradley Arant Boult Cummings LLP
Jan
4
2024
Not So Fast My Friend: Alabama Medical Commission Halts Issuance of Integrated (and Probably Dispensary) Licenses Bradley Arant Boult Cummings LLP
Jan
4
2024
Brand Selection Primer for Emerging Healthy F&B Companies Foley & Lardner LLP
Jan
4
2024
FDA Announces Availability of Cosmetics Direct Portal and Publication of Final Guidance on Cosmetic Facility Registration and Product Listing ArentFox Schiff LLP
Jan
4
2024
Acetaminophen MDL: Judge Excludes All of Plaintiffs’ Causation Experts Pursuant to Newly-Amended FRE Rule 702 Foley & Lardner LLP
Jan
4
2024
Espresso Yourself: When Prosecution History as a Whole Doesn’t Demonstrate Clear, Unmistakable Disclaimer McDermott Will & Emery
Jan
4
2024
Same Applicant, Similar Claims Support Obviousness-Type Double Patenting Rejection McDermott Will & Emery
Jan
3
2024
NIOSH Reviews Past Nanotechnology Guidance and Needs for Future Research Bergeson & Campbell, P.C.
Jan
3
2024
DOT Random Drug and Alcohol Testing Rates for 2024 Jackson Lewis P.C.
Jan
3
2024
Defending Psychedelics: Congress Includes Psychedelic Provisions in Defense Authorization Act Bradley Arant Boult Cummings LLP
Jan
3
2024
Federal Circuit Clarifies Reach of “Artificial” Act of Patent Infringement Proskauer Rose LLP
Jan
3
2024
Unpacking Averages: The Seasonality of FDA 510(k) Decision-Making and the Impact of Michigan Playing for a National Championship Epstein Becker & Green, P.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins